1. Borawski J, Naumnik B, Mysliwiec M.Tissue factor and thrombomodulin in hemodialysis patients: Associations with endothelial injury, liver disease and erythropoietin therapy. Clin Appl Thromb Hemost2002;8:359-359.
2.
2. Borawski J, Pawlak K, Mysliwiec M.Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients. Nephron2002;91:671-671.
3.
3. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int1999;55:648-648.
4.
4. Borawski J, Mysliwiec M.Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost2002;8:77-77.
5.
5. Aguilera A, Selgas R, Ruiz-Caravaca ML, et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int1999;19(Suppl 2):161-161.
6.
6. Allegra A, Buemi M, Corica F, et al. Erythropoietin administration induces an increase of serum levels of soluble E-selectin and soluble intercellular adhesion molecule 1. Nephron1999;82:361-361.
7.
7. Christensson AG, Danielson BG, Lethagen SR.Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis. Nephrol Dial Transplant2001;16:313-313.
8.
8. Carlini RG, Obialo CI, Rothstein M.Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens1993;6:103-103.
9.
9. Takahashi K, Totsune K, Imai Y, et al. Plasma concentrations of immunoreactive endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci1993;80:47-47.
10.
10. Naumnik B, Borawski J, Pawlak K, et al. Effect of hemodialysis on plasma levels of vascular endothelial markers. Clin Appl Thromb Hemost2002;8:245-245.